Compare CNVS & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNVS | NSRX |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 53.5M |
| IPO Year | 2016 | N/A |
| Metric | CNVS | NSRX |
|---|---|---|
| Price | $2.42 | $2.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $9.00 | ★ $20.50 |
| AVG Volume (30 Days) | ★ 321.0K | 125.0K |
| Earning Date | 02-17-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $78,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $84.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 59.13 | N/A |
| 52 Week Low | $1.77 | $2.60 |
| 52 Week High | $7.39 | $9.99 |
| Indicator | CNVS | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.20 | 25.26 |
| Support Level | $2.37 | N/A |
| Resistance Level | $3.47 | $6.39 |
| Average True Range (ATR) | 0.23 | 0.46 |
| MACD | -0.09 | -0.19 |
| Stochastic Oscillator | 1.26 | 0.77 |
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.